Prime Medicine, Inc. Expected to Post Q3 2022 Earnings of ($1.04) Per Share (NYSEARCA:PRME)
Prime Medicine, Inc. Expected to Post Q3 2022 Earnings of ($1.04) Per Share (NYSEARCA:PRME)
Prime Medicine, Inc. (NYSEARCA:PRME – Get Rating) – Investment analysts at Jefferies Financial Group issued their Q3 2022 earnings estimates for Prime Medicine in a report released on Monday, November 14th. Jefferies Financial Group analyst E. Yang forecasts that the company will post earnings of ($1.04) per share for the quarter. Jefferies Financial Group currently has a "Buy" rating and a $25.00 target price on the stock. Jefferies Financial Group also issued estimates for Prime Medicine's Q4 2022 earnings at ($0.25) EPS, FY2022 earnings at ($2.83) EPS, FY2023 earnings at ($1.18) EPS, FY2024 earnings at ($1.44) EPS, FY2025 earnings at ($1.64) EPS and FY2026 earnings at ($1.90) EPS.
Prime Medicine，Inc.(NYSEArca：PRME-GET Rating)-傑富瑞金融集團的投資分析師在11月14日星期一發布的一份報告中發佈了他們對Prime Medicine 2022年第三季度的收益預期。傑富瑞金融集團分析師E.Yang預計，該公司本季度每股收益將達到1.04美元。傑富瑞金融集團目前對該股的評級為買入，目標價為25.00美元。傑富瑞金融集團還發布了對Prime Medicine 2022財年第四季度每股收益(0.25美元)、2022財年每股收益(2.83美元)、2023財年每股收益(1.18美元)、2024財年每股收益(1.44美元)、2025財年每股收益(1.64美元)和2026財年每股收益(1.90美元)的預期。
Several other analysts also recently weighed in on the company. The Goldman Sachs Group assumed coverage on Prime Medicine in a research note on Monday. They set a "neutral" rating and a $22.00 target price for the company. JPMorgan Chase & Co. initiated coverage on Prime Medicine in a research report on Monday. They issued an "overweight" rating and a $27.00 target price on the stock. Finally, Morgan Stanley assumed coverage on shares of Prime Medicine in a research note on Monday. They issued an "equal weight" rating and a $23.00 price target for the company.
其他幾位分析師最近也加入了對該公司的看法。週一，高盛在一份研究報告中對春華醫藥進行了報道。他們為該公司設定了“中性”評級和22.00美元的目標價。摩根大通公司週一在一份研究報告中提出了對Prime Medicine的報道。他們對該股的評級為“增持”，目標價為27美元。最後，摩根士丹利在週一的一份研究報告中對春華醫藥的股票進行了報道。他們對該公司進行了“同等權重”評級，並設定了23.00美元的目標價。
Prime Medicine Stock Performance
優質醫藥類股表現
Shares of PRME opened at $18.22 on Wednesday. Prime Medicine has a 12 month low of $14.52 and a 12 month high of $21.73. The stock's 50-day moving average is $19.55 and its two-hundred day moving average is $19.99.
PRME股價週三開盤報18.22美元。Prime Medicine的12個月低點為14.52美元，12個月高位為21.73美元。該股的50日移動均線切入位為19.55美元，200日移動均線切入位為19.99美元。
Insider Buying and Selling
內幕買賣
In related news, Director Thomas Cahill acquired 400,000 shares of the firm's stock in a transaction on Monday, October 24th. The shares were bought at an average cost of $17.00 per share, with a total value of $6,800,000.00. Following the completion of the acquisition, the director now owns 5,305,679 shares of the company's stock, valued at $90,196,543. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, major shareholder 2019 Gp L.L.C. Gv purchased 800,000 shares of Prime Medicine stock in a transaction on Monday, October 24th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $13,600,000.00. Following the completion of the transaction, the insider now directly owns 11,522,248 shares in the company, valued at $195,878,216. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Thomas Cahill acquired 400,000 shares of the company's stock in a transaction dated Monday, October 24th. The shares were purchased at an average cost of $17.00 per share, with a total value of $6,800,000.00. Following the acquisition, the director now owns 5,305,679 shares of the company's stock, valued at approximately $90,196,543. The disclosure for this purchase can be found here.
在相關新聞中，董事託馬斯·卡希爾在10月24日(星期一)的一次交易中收購了400,000股該公司股票。這些股票的平均價格為每股17.00美元，總價值為6,800,000.00美元。收購完成後，董事現在擁有該公司5305679股股票，價值90,196,543美元。此次收購是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過美國證券交易委員會網站。另一則消息是，大股東2019 GP L.L.C.GV在10月24日(星期一)的一筆交易中購買了80萬股Prime Medicine股票。這些股票是以每股17.00美元的平均成本購買的，總交易額為13,600,000.00美元。交易完成後，該內部人士現在直接擁有該公司11,522,248股，價值195,878,216美元。此次收購是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過此超鏈接。此外，在一筆日期為10月24日(星期一)的交易中，董事託馬斯·卡希爾收購了400,000股該公司股票。這些股票的平均價格為每股17.00美元，總價值為6,800,000.00美元。收購完成後，董事現在擁有5305679股公司股票，價值約90,196,543美元。關於這次購買的披露可以找到這裏.
About Prime Medicine
關於Prime Medicine
Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
Prime Medicine，Inc.是一家生物技術公司，通過部署基因編輯技術提供基因療法來治療疾病。它為Prime Edants提供了Prime Editor蛋白質和pegRNA，前者包括CaS蛋白質和逆轉錄酶之間的融合；後者將Prime Editing定位於特定的基因組位置，並提供對目標DNA序列進行所需編輯的模板。
譯文內容由第三人軟體翻譯。